Amedin

Quick links to important sections

Amedin

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amedin

What is Amedin? An Overview

Property Description
Active ingredient Amlodipine (as besilate salt)
Form Oral tablet
Pharmacological class Dihydropyridine Calcium Channel Blocker (CCB)
General purpose To manage blood pressure and cardiovascular flow
Origin Synthetic

What is Amedin and What Drug Class Does it Belong To?

Amedin is a synthetic, prescription-only medication identified by its single active component, Amlodipine (besilate salt). Pharmacologically, it is classified as a Dihydropyridine Calcium Channel Blocker (CCB), placing it within the category of Antihypertensive Agents designed to modulate blood vessel function. This classification indicates the medicine is intended to help control factors related to high arterial pressure and cardiovascular resistance.

The medicine is clinically recognized for its long-acting properties, a characteristic supported by pharmacological studies that demonstrate sustained therapeutic coverage throughout the day. This prolonged action allows for a consistent and stable approach to the long-term management of cardiovascular parameters, distinguishing it from shorter-acting compounds.


Composition and Form: The Amlodipine Oral Tablet

Amedin is manufactured as a single-ingredient oral tablet, the standard and reliable form for systemic administration. Its composition focuses solely on the therapeutic substance, Amlodipine besilate, which is a synthetically derived chemical compound. The tablet formulation includes standard solid excipients necessary for stability and proper absorption. As a single-ingredient product, Amedin provides precise control over the introduction of Amlodipine into the system, avoiding the complexities of fixed-dose combination products.


How Does Amedin Generally Affect Blood Flow and Pressure?

Amedin influences the circulatory system by promoting the relaxation and widening of the peripheral arteries, a process known as vasodilation. This effect is achieved through the drug’s role as a slow-channel blocker, which inhibits the influx of calcium ions into the smooth muscle cells of the arterial walls, the elements responsible for contraction. This mechanism is widely understood and researched in cardiology, supporting its reliable use.

By inhibiting calcium, the drug reduces the stiffness and overall resistance within the blood vessels. This action reduces the overall peripheral vascular resistance, meaning the heart encounters less force when circulating blood, thereby contributing to a generalized lowering of blood pressure.

Regulatory References

  1. MedlinePlus Drug Information
  2. NIH/NLM Drug Information

What side effects are possible with Amedin?

Possible Side Effects and Safety Information

Adverse reactions associated with Amedin (Amlodipine) are formally classified by frequency and grouped according to the systems or organs affected, as documented in official regulatory safety labels. This classification framework defines which effects are generally expected and which are rare or serious.

Frequency and System Classification

Oedema (swelling) is the most frequently reported event, classified as Very Common (ge 1/10) in official documentation. Other effects are classified as Common (ge 1/100 to <1/10), including neurological effects such as headache, dizziness, and somnolence, alongside vascular effects like flushing and palpitations, and general disorders such as fatigue and ankle swelling.

Less frequently reported adverse reactions are classified as Uncommon or Rare. These affect various system-organ classes, including the gastrointestinal system (e.g., nausea, abdominal pain), the nervous system (e.g., tremor, syncope), and the skin (e.g., rash, pruritus).

Serious Adverse Reactions and Contextual Safety

Serious adverse reactions, such as Myocardial Infarction, Worsening Angina, Pancreatitis, Hepatitis, and severe skin reactions like Stevens-Johnson syndrome, are documented as Very Rare occurrences. The label notes that the worsening of angina or acute myocardial infarction can develop after starting or increasing the dose, particularly in individuals with pre-existing severe coronary artery disease.

Official safety notes include specific considerations for certain populations: clearance is reported to be decreased in older adults, and the half-life is prolonged in patients with hepatic impairment. The use of Amedin is restricted by official contraindications, including known hypersensitivity to the active ingredient or other dihydropyridine derivatives, severe hypotension, and cardiogenic shock.

Overdose and Emergency Response

Amedin Overdose and when to seek help

The official regulatory profile for Amedin (Amlodipine) overdose is defined by the severe cardiovascular effects resulting from excessive exposure to this Calcium Channel Blocker, which mandate immediate professional attention.

Element Regulatory Description
Documented Overdose Signs Profound and prolonged systemic hypotension; excessive peripheral vasodilation; reflex tachycardia; bradycardia; potential for atrioventricular conduction delay.
Severe Outcomes Circulatory shock, cardiovascular collapse, and the risk of death are officially documented consequences of severe overexposure.

Emergency Response and Supportive Management

Classification Detail Regulatory Statement
Immediate Action Required Seek immediate medical attention or contact emergency medical services immediately for any known or suspected overdose.
Antidote Status No specific antidote is known for Amlodipine overexposure; management is supportive and symptomatic.

Official Overdose Statements

Profound overexposure is documented to result in life-threatening hypotension and severe vasodilation. Treatment is focused on symptomatic and supportive measures, including the administration of intravenous fluids, vasopressor agents to raise blood pressure, and consideration of intravenous calcium. Due to the long elimination half-life of Amlodipine, continuous hospital monitoring and observation of cardiovascular function are officially required for an extended period, even if initial symptoms appear resolved, to manage the potential for delayed effects.

Therapeutic Uses of Amedin

What Amedin Treats: Main Uses and Benefits

Amedin (Amlodipine) is commonly used for the long-term management of cardiovascular conditions, focusing on the relief of specific symptoms and the control of conditions marked by increased physiological stress. The primary therapeutic domains involve managing symptoms related to systemic imbalance and addressing symptoms related to physical discomfort. It is used in conditions that involve sustained high pressure and coronary artery disease. The medication is considered relevant for easing symptoms across therapeutic domains, which include hypertension, chronic stable angina, and vasospastic angina.


Managing Chronic Symptom Domains

Amedin is applied when appropriate in clinical contexts where conditions presenting with systemic discomfort, specifically systemic arterial pressure elevation, are chronic or persistent. The medicine assists with maintaining functional stability when symptoms are more noticeable by supporting the control of elevated blood pressure. Furthermore, it is applied across domains where additional symptomatic support is needed for chest discomfort, which supports patients during episodes of heightened discomfort.

Quick Fact: Supportive Role in Chest Discomfort Amedin may assist with managing the symptoms related to physical discomfort, specifically the recurrent or episodic manifestations of angina.

Eligibility and Restrictions for Use

The eligibility profile for Amedin (Amlodipine) is defined by absolute prohibitions and conditional use restrictions documented by regulatory authorities. The information below details which populations are permitted, restricted, or prohibited from using the medicine according to official governmental labeling.

Contraindications and Restrictions

Regulatory Status Affected Population or Condition
Contraindicated Patients with known hypersensitivity to Amlodipine or dihydropyridine derivatives. This status also applies to individuals experiencing severe hypotension, cardiogenic shock, or obstruction of the left ventricular outflow tract, such as high-grade aortic stenosis.
Conditional Use Hepatic Impairment: Requires caution and consideration of a lower initial dose due to potential reduced drug clearance. Severe Heart Failure (NYHA Class III/IV): Should be used with caution.

Age and Reproductive Status Eligibility

Amedin is approved for use in adults for all labeled indications. For the pediatric population aged 6 to 17 years, use is restricted to the treatment of hypertension only, with safety and efficacy not established for children under 6 years of age. Older adults are generally eligible for standard regimens but require careful consideration.

Regarding reproductive status, use during pregnancy is permitted only when the defined potential benefit justifies the potential risk to the fetus. The official regulatory label advises discontinuing nursing when the medicine is administered to breastfeeding mothers. Renal impairment does not require a dosage adjustment.

What should I know about interactions with other medicines?

Amedin (amlodipine) can interact with a range of other medicines and products, primarily due to its metabolism by the CYP3A4 enzyme in the liver. These interactions can affect Amedin's levels or the levels of the co-administered drug, potentially leading to increased effects or side effects.

Interacting Agents Interaction Outcome and Restriction
Strong/Moderate CYP3A4 Inhibitors (e.g., clarithromycin, erythromycin, ketoconazole, verapamil, diltiazem) May significantly increase Amedin exposure, potentially raising the risk of hypotension (low blood pressure). Close clinical monitoring and possible dose adjustments are required.
Strong CYP3A4 Inducers (e.g., rifampicin, St. John's Wort) May lead to variable Amedin plasma concentrations. Blood pressure monitoring and dose regulation should be considered during and after co-administration.
Simvastatin (a cholesterol-lowering medicine) Amedin increases Simvastatin exposure. The dose of Simvastatin must be limited to a maximum of 20 mg daily when taken with Amedin due to the increased risk of muscle-related side effects.
Tacrolimus (an immunosuppressant) Amedin may increase Tacrolimus blood levels. Monitoring of Tacrolimus blood levels and its dose adjustment is necessary to avoid toxicity.
Grapefruit or Grapefruit Juice Not recommended for consumption with Amedin as it can increase the drug's availability and blood pressure-lowering effect.
Dantrolene (infusion) (used for malignant hyperthermia) Avoid co-administration in susceptible patients due to the risk of hyperkalemia (high potassium levels).

No dose adjustment is typically required when Amedin is administered with common blood pressure medications such as thiazide diuretics, beta blockers, or angiotensin-converting enzyme inhibitors. Elderly patients may experience a more pronounced effect from pharmacokinetic variations due to CYP3A4 inhibitors, requiring cautious dose adjustment.

Mechanism of Action

️ Selective L-Type Calcium Channel Inhibition

Amedin binds to and inhibits voltage-dependent L-type calcium channels ( CaV1.2), specifically within the cell membranes of vascular smooth muscle and myocardial tissue. The inhibition results in a reduction of the transmembrane calcium ion influx into these cells, thereby decreasing the intracellular calcium concentration required for excitation-contraction coupling. The drug exhibits greater functional effect on vascular smooth muscle compared to myocardial tissue.


Vascular and Cardiac Muscle Contractility

Reduced intracellular calcium concentrations result in decreased contractility of vascular smooth muscle, leading to vasodilation (an increase in the diameter of arterial blood vessels). This decrease in vascular smooth muscle contractility reduces the arterial wall tension and peripheral vascular resistance (PVR), which represents the load opposing ventricular ejection.


️ Hemodynamic Modulation

The systemic vasodilation leads to a reduction in total peripheral resistance (TPR). This reduction in TPR causes a systemic decrease in arterial blood pressure. Additionally, the mechanism induces coronary artery dilation which influences myocardial oxygen supply dynamics.

Dosage and Administration Information

Amedin (Amlodipine) is administered exclusively via the oral route as a conventional tablet. The standardized dosing pattern mandates once daily administration to ensure consistent therapeutic coverage. This medication can be taken with or without food, establishing flexibility for the patient regarding the timing of the daily dose.

Standard Labeled Dosing Regimens

The standard starting dose for adult usage in approved contexts is 5 mg taken once daily. Based on established clinical protocols, the maximum recommended daily dose for all adult indications is 10 mg. The tablet is supplied in official strengths of 2.5 mg, 5 mg, and 10 mg.

Dosage Adjustment and Special Populations

Dosage adjustment, known as titration, must be undertaken slowly due to the drug's properties. The official protocol requires a minimum waiting period of 7 to 14 days between any dose increases to allow the medication to fully reach a stable level in the body before evaluating the response.

For certain patient populations, a reduced initial dose is officially specified. Older adults and individuals with hepatic impairment should typically begin treatment with the lowest available starting dose of 2.5 mg once daily, and subsequent dose increases should proceed slowly. For pediatric patients (aged 6 to 17) being treated for hypertension, the approved dosing range is 2.5 mg up to a maximum of 5 mg once daily. If a dose is missed, standard guidance suggests skipping the missed dose if it is near the time for the next scheduled dose, and never taking a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Amedin (Amlodipine)

The research evidence for Amedin primarily comes from clinical trials, including Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses, which are the main sources relied upon by regulatory bodies worldwide. These studies examine how the medicine was studied across its approved uses compared to either a placebo or other established therapies.


Evidence for use in Hypertension (High Blood Pressure)

The research exploring Amlodipine's use for high blood pressure has been studied in numerous trials, including large Randomized Controlled Trials (RCTs). Researchers primarily tracked changes in specific physical measurements, such as systolic and diastolic blood pressure (BP), and reported on the percentage of study participants whose BP measurements moved toward predefined target ranges. Long-term studies monitored outcomes reflecting physiological strain, specifically assessing the frequency of major cardiovascular events (e.g., heart attack and stroke) over follow-up periods that can extend for several years. Data focused on the optimal management of patients with severe or resistant hypertension often rely on specific subgroup analyses rather than dedicated RCTs.


Evidence for use in Chronic Stable Angina

The research for chronic stable angina consists of Randomized Controlled Trials where Amlodipine was evaluated in comparison to a placebo or other standard medications. Research examined outcomes related to physical discomfort. Studies monitored the frequency and duration of chest discomfort episodes reported by participants and the consumption of emergency relief medication. Research also focused on functional endpoints such as exercise tolerance tests. Findings indicate patterns related to the necessity of rescue medication use during the study period. The research provides limited direct insight into long-term changes in underlying coronary artery pathology.


Research in Specific Patient Populations

Amlodipine was studied for use in specific groups outside of the general adult population. For older adults, evidence is available, often derived from subgroup analyses within larger RCTs. Research has also been conducted for children aged 6 to 17 years with hypertension exploring outcomes related to physiological strain, specifically blood pressure. These studies monitored changes in blood pressure compared to a placebo. Data for certain other specialized groups remain insufficient or limited to small studies.

Key Studies & References Clinical Guideline: Hypertension in adults: diagnosis and management (NICE Guideline NG136)

Frequently Asked Questions (FAQ)

Common questions about Amedin (FAQ)

Q: How quickly does Amedin start working for its intended purpose?

After an oral dose, Amedin's concentration in the blood typically reaches its highest level between 6 and 12 hours. This gradual process results in a slow onset of the blood pressure-lowering effect, which is consistent with the drug’s long-acting properties, as described in official product information.

Q: What is the expected timeline for Amedin's full effect?

Studies on Amedin’s activity show that a stable level (called a steady-state plasma concentration) is reached only after 7 to 8 days of taking the medication daily. This prolonged property allows the anti-hypertensive effect to be maintained throughout the day with chronic, once-daily administration.

Q: What happens if I stop taking Amedin after a long period of use?

Official information indicates that blood pressure levels slowly return to the patient’s untreated baseline over approximately 7 to 10 days after stopping the medication. There is no evidence in regulatory documents of a sudden, unwanted increase in blood pressure (known as a rebound effect) when treatment is discontinued.

Q: Does Amedin cause dependence or withdrawal symptoms?

According to regulatory guidance, Amedin is not associated with the potential for recreational use or abuse. Official drug information confirms that the medicine is not known to cause physical dependence or withdrawal symptoms upon stopping treatment.

Q: Is it common to feel tired or dizzy when first starting Amedin?

Regulatory documents classify dizziness and fatigue (tiredness) as Common side effects. Although official labels do not specify a higher frequency only at the very start, these general adverse effects may be noticed.

Q: Does Amedin affect sleep patterns or cause insomnia?

Official safety labels indicate that somnolence (sleepiness or drowsiness) is listed as a Common side effect of the medication. Insomnia (difficulty falling or staying asleep) is also noted, but as a less frequent, Uncommon side effect.

Q: Is it possible for Amedin to cause long-term side effects?

Official documentation tracks rare and very rare serious reactions, such as hepatitis (liver inflammation) and pancreatitis. These effects, while infrequent, are part of the long-term safety profile and are monitored during chronic use of the medicine.

Q: Will Amedin affect my ability to drive or operate machinery?

Official labeling advises that Amedin may cause side effects such as dizziness, headache, or fatigue. If these effects occur, an individual's ability to drive or operate complex machinery may be impaired, and individuals are advised to monitor their response before engaging in such activities.

Q: Is Amedin a generic or a brand-name medication?

The active ingredient, amlodipine, is the recognized generic name. It is an approved generic drug that is also marketed under various brand names, such as Norvasc, according to official drug information.

Q: Is Amedin considered a controlled substance by regulatory bodies?

Amlodipine is a non-narcotic prescription drug that is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or similar international bodies. It is not listed as having any potential for abuse or dependency.

Q: Can women who are pregnant or breastfeeding use Amedin?

Regulatory guidance states that use during pregnancy is permitted only if the potential benefit justifies the potential risk to the fetus. For breastfeeding mothers, the official label advises considering discontinuing nursing while the medicine is being administered.

Q: Is Amedin safe for people who have liver problems?

In official guidance, treatment with Amedin involves caution for individuals with hepatic impairment (liver problems) because the body processes the medicine more slowly. A lower starting dose is often specified for this population.

Q: Can Amedin be used alongside alcohol (informational query)?

Regulatory guidance advises that consuming alcohol with Amedin may result in an additive effect in lowering blood pressure. This may increase the risk of side effects like dizziness, lightheadedness, or fainting.

Q: Does Amedin interact with birth control pills or other hormonal medications?

Official interaction data indicates that Amedin may increase the blood levels of the progestin drospirenone, an ingredient found in certain hormonal contraceptives. Official information indicates that monitoring may be considered when these medications are taken together long-term.

Q: Can Amedin affect blood pressure or heart rate?

Amedin’s main purpose is to reduce blood pressure by widening blood vessels. While the drug does not typically lead to a significant change in heart rhythm, palpitations (a rapid or irregular heartbeat sensation) are listed as a Common side effect in official documents.

Q: Does Amedin interact with substances like caffeine or nicotine?

Official warnings note that nicotine can raise blood pressure and heart rate, potentially counteracting Amedin's intended benefit. No direct interaction with caffeine is explicitly listed in primary regulatory documents.

Q: Why is Amedin sometimes prescribed at different dosages for the same condition?

Amedin is prescribed at different dosages to allow for a slow process called dose titration, as described in regulatory documents. This process is used to find the lowest effective dose for the individual patient that controls blood pressure while minimizing side effects.

Q: What official research evidence is available regarding Amedin's use?

The regulatory approval of Amedin is supported by data from Randomized Controlled Trials (RCTs) and systematic reviews. These studies tracked specific measurements, such as changes in systolic and diastolic blood pressure, and monitored the frequency of major cardiovascular events.

Q: How is the safety of Amedin monitored by regulatory agencies?

Regulatory bodies continuously monitor the safety of Amedin through post-marketing surveillance systems. These systems collect and review reports of adverse events from healthcare professionals and the public, ensuring the official safety label is kept up-to-date.

Q: Why do official documents list so many potential side effects for Amedin?

The extensive list of side effects reflects the strict reporting requirements of regulatory agencies (like the FDA and EMA). Any event observed in clinical trials or reported post-marketing is listed, even if the frequency is low or the exact cause-and-effect link with the medicine is not definitively proven.

Q: Is it normal to feel no different after starting Amedin for the first few days?

Yes, it is common to feel no immediate physical change, given that the effect on blood pressure is gradual. The full stable level of the medicine in the body is achieved only after about 7 to 8 days of consistent daily dosing.

Q: What impact does Amedin have on kidney function?

Studies show that Amedin can decrease the resistance and increase blood flow within the blood vessels of the kidney. Regulatory guidance notes that renal impairment (kidney disease) itself does not require a dosage adjustment because the drug is primarily processed by the liver.

Q: Does taking Amedin affect fertility in men or women?

Official documents state there is no evidence to suggest Amedin reduces fertility in women. In men, reversible biochemical changes in sperm have been reported in some patients, though the clinical significance of these findings is uncertain.

Q: What is the official classification of Amedin's potential for misuse?

Amedin is officially classified as a drug with no known potential for abuse or misuse. It is not scheduled as a controlled substance by regulatory agencies.

Q: What is the risk of overdose with Amedin?

Taking too much Amedin can lead to symptoms related to severe blood vessel widening. Overdose can cause profound and prolonged low blood pressure (hypotension) and potentially shock, which are considered medical emergencies.

Q: Is Amedin safe for the elderly population (over 65)?

The drug is approved for use in older adults. However, due to potentially decreased clearance, regulatory guidance specifies starting treatment with the lowest available dose to reduce the risk of adverse effects.

How should Amedin be stored and disposed of?

Official Storage and Disposal Requirements

Storage Conditions

Amedin (Amlodipine) tablets must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with permitted excursions to 15 C to 30 C (59 F to 86 F). The medicine must be protected from light and moisture to ensure stability. Official labeling mandates storing the tablets in their original container and keeping it tightly closed in a dry place. It is essential to keep Amedin out of the sight and reach of children.

Disposal Instructions

Expired or unused Amedin tablets must not be discarded in household waste or flushed down the toilet (wastewater). Disposal must comply with local regulations for medicinal products, often requiring the medicine to be returned to a pharmacy or an approved collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amedin found in:

A-Z Index: